SN68 - MetaNova Labs: Crypto as a Cure for Broken Biotech Incentives

What You Need to Know

The pharmaceutical industry is broken, not scientifically, but structurally.

Web2 pharma, or Traditional Pharma has long operated behind locked doors. Billion-dollar drugs are developed in black boxes, governed by institutions with deep pockets and shallow incentives. R&D is slow, data is siloed, and scientific curiosity is often penalized in favor of patent protection and profit margins. Billions are spent annually, but real breakthroughs remain rare.

Web3, meaning The Pharmaceutical industry having a foundation made on decentralized incentive-based systems offers a way out, but until now, it lacked the infrastructure to deliver real drug discovery at scale.

But what if the entire process could be reengineered from the bottom up?

This article unpacks how Subnet 68 - MetaNova Labs ( @metanova_labs ), built on the Bittensor network, is transforming the landscape of drug discovery. Not by tweaking the old system but by replacing its incentive structure entirely.

We'll explore:

• Why Web2 pharma is structurally misaligned with innovation
• The failed first wave of Web3 pharma efforts
• How SN68 turns discovery into a permissionless market
• The economic logic of rewarding models, not institutions
• How a decentralized chemistry engine can outperform traditional labs
• What success here could mean for the future of all scientific research

If you're interested in the frontier of crypto, science, and coordination, this is your map to one of the most promising subnets in the Bittensor ecosystem and a live promising experiment in building the future of biotech.

From Web2 Pharma to Web3 Discovery

The pharmaceutical industry today operates in a Web2 framework:
centralized, opaque, and heavily gatekept. Drug discovery is managed by a few powerful incumbents - Big Pharma firms, elite academic institutions, and capital-rich biotech startups - who guard intellectual property behind closed doors and prioritize defensible IP over broader innovation.

In this model:

• Data is siloed
• Incentives are slow and misaligned
• Breakthroughs happen in the shadows of bureaucracy

And most importantly, the system doesn't reward exploration - it punishes it.

Even with billions spent annually on R&D, the average cost to bring a new drug to market is skyrocketing, timelines are stretching, and success rates remain dismal. The bottleneck isn't just scientific - it's structural.

Enter Web3.

The world is undergoing a silent transformation. At the heart of this shift is Web3 - a new technological and economic framework that fundamentally reimagines how people, systems, and capital coordinate.

For decades, progress has depended on centralized entities. Whether it's publishing a scientific paper, launching a startup, or conducting clinical research, participation has required the approval of gatekeepers: publishers, banks, venture capitalists, pharmaceutical giants. These institutions, while historically effective, are not built for the speed, complexity, or inclusivity that today's problems demand.

Web3 introduces a different paradigm. It replaces centralized control with decentralized protocols. It replaces trust in intermediaries with trust in code. And it replaces exclusionary processes with open, permissionless participation, offering a radically different framework. In this new paradigm, innovation can be:

• Distributed across a global network of miners and models
• Rewarded in real-time based on merit, not reputation
• Open-sourced and monetizable from day one

Instead of relying on legacy hierarchies, Web3-native drug discovery platforms like Subnet 68 - MetaNova Labs turn science into a permissionless market. Miners compete to prioritize novel with potential to become medicines. Delegators stake toward strategies they believe in. Every successful hit feeds a loop of better data, smarter models, and more valuable outputs.

The opportunity isn't just to do drug discovery differently-it's to rebuild the incentive layer behind the entire scientific process.

This isn't the "crypto-for-pharma" pitch. It's the start of a shift: from patents to protocols, from gated R&D to collaborative networks, and from centralized science to composable, monetizable molecular intelligence.

Marc Andreessen, founder of a16z and early investor in both Web2 and Web3 startups, has noted that "Web3 gives users ownership of the internet. That's not a small shift-it's the most significant thing to happen to computing since the invention of the browser." This ownership principle extends beyond content or identity-it applies to discovery itself.

In industries like pharmaceuticals, where centralization has created massive inefficiencies, Web3's coordination advantages are even more profound. The current system is plagued by perverse incentives. Research is hoarded instead of shared. Innovation is stifled by fear of IP theft. And capital is funneled toward projects that fit investor narratives rather than long-term health outcomes.

A Quick Primer on In Vitro Drug Discovery

In vitro (Latin for "in glass") refers to the process of studying biological reactions outside of a living organism - typically in petri dishes, test tubes, or culture flasks. In pharmaceutical R&D, in vitro experiments are critical early steps, used to:

• Screen large libraries of compounds for biological activity
• Study drug-target interactions
• Assess toxicity and side effects
• Narrow down candidates for further testing in animals or humans (in vivo)

While scientifically essential, traditional in vitro methods are slow, expensive, and resource-intensive. Each test must be designed, run, and analyzed manually - often by highly trained scientists using expensive reagents and equipment.

Moreover, scaling these experiments is difficult, as each additional compound or variable exponentially increases cost and time. This bottleneck slows innovation and makes early-stage R&D prohibitively expensive for all but the biggest players.

Traditional in vitro methods are the gold standard, but they are expensive, slow, and gatekept.

MetaNova Labs, through Bittensor's SN68, abstracts discovery into a decentralized compute economy, where miners compete to prioritize and evolve molecules at internet scale, and where rewards are given based on results, not reputation.

This shift doesn't replace the wet lab - it primes it. SN68 can identify promising leads faster and cheaper, which can then be validated in vitro. It's a discovery engine for the age of decentralized science.

-> Enjoying the read ?
Find more Articles on https://www.bittensor.ai/learning-hub

-> Join the discussion
https://discord.gg/2aPayeUk67

Subnet 68 (MetaNova Labs)

1. The Real Innovation Isn't Just the Molecules - It's the Model

The pharmaceutical industry is a $1.5 trillion behemoth with a well-known problem: misaligned incentives.

1. Researchers chase publishable results, not usable drugs
2. Pharma chases IP defensibility, not molecular diversity
3. Venture capital chases hype curves, not long timelines
4. And patients? They wait

MetaNova Labs, with Subnet 68 (NOVA) on Bittensor, is building a different path - one where economic incentives, compute rewards, and data feedback loops are all directly aligned with molecular breakthroughs.

It's not just about molecules anymore. It's about building the first decentralized biotech R&D platform that pays for results, evolves over time, and belongs to no one.

2. How Bittensor Fixes Incentives in Drug Discovery

In traditional biotech:

• Scientists are paid regardless of model quality
• Investors profit on hype, not molecule utility
• IP is hoarded, not composable
• And experimentation is limited by funding, not compute

In Subnet 68:

• Miners are rewarded for prioritizing diverse, synthesizable molecules
• Models improve over time via public signal-based training
• Tokenized incentives reward real-world utility (not just speculation)
• On-chain coordination means models are open, testable, and composable

It's a platform, not a pipeline.

3. Why the Combinatorial Chemistry Engine Still Matters

Yes, the recent combinatorial update is technically impressive. It enables miners to generate new compounds via reactions like reductive amination, unlocking billions of synthesizable molecules. That expands the search space and drives higher hit rates.

But what really matters is why that update exists:

Because the subnet is economically rewarded for generating useful, novel chemistry at scale.

In Web2 biotech, that update would be hidden in a lab. In SN68, it's live, on-chain, and being stress-tested by a decentralized swarm of miners, all financially incentivized to produce something valuable.

4. Platform Effects in Action

Here's what's emerging:

• Feedback flywheel: Better molecules → better models → better future molecules
• Decentralized infrastructure: No need to raise a Series B to scale chemistry pipelines
• Composability: Other subnets, researchers, or pharma partners can build on top of the same outputs
• IP redefined: Instead of owning molecules, SN68 owns the capacity to create them
• Open source → Open profit: The better the network performs, the more emissions miners and delegators receive

In short: this isn't a feature update. It's a new foundation for biotech R&D.

5. Market Potential: What If It Works?

If SN68 succeeds, it will:

• Make molecular discovery a public good, not a private secret
• Create a transparent, programmable API for generating drug leads
• Offer a model that other scientific disciplines (e.g. materials science, agriculture) can copy
• Attract capital that cares about real outcomes, not just token speculation

And most critically, it will show that Web3 isn't just a funding mechanism for science - it can be the lab.

6. Final Thought: Why MetaNova Labs Had to Do It

The centralized, siloed, black-box model of biotech is fundamentally misaligned with what science needs: exploration, failure, iteration, and scale.

No existing system could incentivize all those simultaneously - until Bittensor.

SN68 isn't just building molecules. It's building a new game where molecules are the byproduct of good incentives.

So yes, the molecules matter. But what matters more is this:

Bittensor just might be the first financial system that pays for curiosity.